Dr. Geynisman Discusses Immunotherapy in RCC

Daniel M. Geynisman, MD
Published: Monday, Oct 23, 2017



Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).

Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.

Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.
 


Daniel M. Geynisman, MD, assistant professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses immunotherapy in metastatic renal cell carcinoma (mRCC).

Patients are excited and willing to participate in clinical trials of immunotherapy, says Geynisman. In RCC, select patients have shown to derive benefit from immunotherapy.

Geynisman says that trials of immunotherapy and targeted therapies will undoubtedly change the treatment paradigm in mRCC.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x